JMJulia Merkel

Julia Merkel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julia Merkel has a total of 11 co-authors. Here are the top co-authors by number of shared publications:

  • Artur Lichtenberg

    Department of Cardiac Surgery and Research Group for Experimental Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich Heine University Hospital, Düsseldorf, Germany

    1 shared publication
  • Carolin Torregroza

    Department of Anesthesiology, Medical Faculty and University Hospital Duesseldorf, Heinrich-Heine-University Duesseldorf, Moorenstr. 5, 40225 Duesseldorf, Germany

    1 shared publication
  • Giovanna Lurati Buse

    Department of Anaesthesiology, Medical Faculty and University Hospital Duesseldorf, Heinrich Heine University Duesseldorf, Duesseldorf, Germany; German Society of Anaesthesiology and Intensive Care (GSAIC) Trials Group

    1 shared publication
  • Hannan Dalyanoglu

    Department of Cardiac Surgery, Medical Faculty, Heinrich Heine University, 40225 Dusseldorf, Germany

    1 shared publication
  • Hug Aubin

    Department of Cardiac Surgery, Medical Faculty and University Hospital Düsseldorf, Heinrich-Heine-University Düsseldorf, 40225 Düsseldorf, Germany

    1 shared publication
  • Markus Werner Hollmann

    Department of Anesthesiology, Amsterdam University Medical Center, Amsterdam, The Netherlands

    1 shared publication

Latest Publications

  • Open Access

    Bilirubin—A Possible Prognostic Mortality Marker for Patients with ECLS

    by Sebastian Bunte, Roland Walz, Julia Merkel, Carolin Torregroza, Sebastian Roth, Giovanna Lurati Buse, Hannan Dalyanoglu, Payam Akhyari, Artur Lichtenberg, Markus W. Hollmann, et al.

    Extracorporeal life support (ECLS) is a promising therapeutic option for patients with refractory cardiogenic shock. However, as the mortality rate still remains high, there is a need for early outcome parameters reflecting therapy success or futility. Therefore, we investigated whether liver enzyme levels could serve as prognostic mortality markers for patients with ECLS. The present study is a retrospective single-center cohort study. Adult patients >18 years of age who received ECLS therapy between 2011 and 2018 were included. Bilirubin, glutamic-oxaloacetic transaminase (GOT), and glutamic-pyruvic-transaminase (GPT) serum levels were analyzed at day 5 after the start of the ECLS therapy. The primary endpoint of this study was all-cause in-hospital mortality. A total of 438 patients received ECLS during the observation period. Based on the inclusion criteria, 298 patients were selected for the statistical analysis. The overall mortality rate was 42.6% (n = 127). The area under the curve (AUC) in the receiver operating characteristic curve (ROC) for bilirubin on day 5 was 0.72 (95% confidence interval (CI): 0.66–0.78). Cox regression with multivariable adjustment revealed a significant association between bilirubin on day 5 and mortality, with a hazard ratio (HR) of 2.24 (95% CI: 1.53–3.30). Based on the results of this study, an increase in serum bilirubin on day 5 of ECLS therapy correlates independently with mortality.